Limitless Pharma: sector benchmark
Where does a company stand against its sector? Every ratio over five fiscal years, with its place among its peers and what that means, ready to print for your client.
Limitless Pharma
Summary
Limitless Pharma does better than half of its sector on 5 of the 8 ratios compared.
- Long-term debt ratiobetter than 95%
- Debt to equitybetter than 91%
- Current ratiobetter than 84%
- Interest coveragebetter than 5%
- Return on assetsbetter than 5%
- Solvencybetter than 9%
Solvency and debt
Solvency is below 91% of 41,204 sector peers: in the least favourable quarter.
Debt to equity is below 91% of 40,686 sector peers: in the most favourable quarter.
The long-term debt ratio is below 95% of 21,483 sector peers: in the most favourable quarter.
Interest coverage is below 95% of 36,771 sector peers: in the least favourable quarter.
Liquidity
The current ratio is above 84% of 41,060 sector peers: in the most favourable quarter.
The quick ratio is above 52% of 41,086 sector peers: more favourable than the median.
The working-capital ratio is above 80% of 41,134 sector peers: in the most favourable quarter.
Profitability
Return on assets is below 95% of 41,307 sector peers: in the least favourable quarter.
Not computable
Return on equity, Net margin, EBITDA margin, Gross margin, Days sales outstanding, Days payable outstanding, Days inventory. This company files the abbreviated or micro schema, in which turnover and purchases are optional; margins and credit terms therefore cannot be taken from its figures.
Source: filed annual accounts (NBB) and main activity (CBE register). Compared per fiscal year with each peer's latest statutory accounts; at least 30 peers per ratio. Prepared on 28 September 2026 via checked.be.